REGULATORY UPDATE: FDA Finalizes HBV Guidance, Allows Blood Establishments to Discontinue HBsAg Testing

November 04, 2026

FDA released a final guidance, Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus, finalizing without changes the July 2025 draft guidance on hepatitis B surface antigen (HBsAg) testing. The guidance also consolidates FDA’s HBV recommendations into a single document. It supersedes FDA’s 1987 and 1991 memoranda, the HBV-specific parts of the 1996 memorandum, and the 2007, 2010, 2011 and 2012 final guidances.

Under the updated final guidance, testing whole blood and blood components for HBsAg is not necessary when each donation is tested for antibody to hepatitis B core antigen (anti-HBc) and for HBV DNA by nucleic acid testing (NAT) using FDA-licensed donor screening tests. FDA based this recommendation on the continued decline of HBV incidence and prevalence in the U.S. since universal infant vaccination began. FDA also cited published data from large U.S. and European blood establishments showing that HBsAg testing does not detect infections missed by both NAT and anti-HBc screening.

The recommendation does not apply to source plasma. FDA continues to recommend that source plasma donations be tested for both HBsAg and HBV DNA by NAT. Anti-HBc testing of source plasma is not recommended. FDA noted it may revisit the source plasma recommendations at a later time, as additional evidence becomes available.

The guidance also makes conforming changes to donor requalification and labeling. These include:

  • updated requalification methods for donors deferred for reactive HBV NAT or anti-HBc results;
  • a requirement to remove the HBsAg statement from the Circular of Information when HBsAg testing is discontinued;
  • updated recommendations for product management and consignee notification.

Blood collection facilities may choose to continue HBsAg testing. Those that do must continue to meet all applicable requirements for managing HBsAg-reactive results. Facilities that discontinue HBsAg testing or make the conforming changes described in the guidance must report them in an annual report under 21 CFR 601.12(d). Facilities that continue HBsAg testing without other changes do not need to report. Implementing an HBV testing strategy other than the one described in the guidance is considered a major change and requires a prior approval supplement.

In September 2025, AABB, America’s Blood Centers and the American Red Cross submitted joint comments welcoming FDA’s recommendation, which reflected requests from their 2022 joint letter.

AABB is developing a new toolkit to assist facilities in the implementation of the guidance. Members with questions may contact AABB Regulatory Affairs.